Therefore, the combination test will reduce the total cost of molecular profiling, at least in Japan, if used for lung adenocarcinoma patients, in which the frequency of the EGFR mutation is approximately 30% or higher [14]. Here, EGFR is linked to lung adenocarcinoma.